Familial Investigations of Childhood Cancer Predisposition
Public ClinicalTrials.gov record NCT03050268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing. While it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition. The purpose of this protocol is to identify novel cancer predisposing genes and/or genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer. PRIMARY OBJECTIVE: * Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members. SECONDARY OBJECTIVE: * Identify novel cancer predisposing genes and/or genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.
Study identification
- NCT ID
- NCT03050268
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,500 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Adenomatous Polyposis
- Adrenocortical Carcinoma
- AML
- BAP1 Tumor Predisposition Syndrome
- Carney Complex
- Choroid Plexus Carcinoma
- Constitutional Mismatch Repair Deficiency Syndrome
- Diamond-Blackfan Anemia
- DICER1 Syndrome
- Dyskeratosis Congenita
- Emberger Syndrome
- Familial Acute Myeloid Leukemia
- Familial Adenomatous Polyposis
- Fanconi Anemia
- Familial Cancer
- Familial Wilms Tumor
- Familial Neuroblastoma
- GIST
- Hereditary Breast and Ovarian Cancer
- Hereditary Paraganglioma-Pheochromocytoma Syndrome
- Hodgkin Lymphoma
- Juvenile Polyposis
- Li-Fraumeni Syndrome
- Lynch Syndrome
- MDS
- Melanoma Syndrome
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2
- Neuroblastoma
- Neurofibromatosis Type 1
- Neurofibromatosis Type II
- Nevoid Basal Cell Carcinoma Syndrome
- Non Hodgkin Lymphoma
- Noonan Syndrome and Other Rasopathy
- Overgrowth Syndromes
- Pancreatic Cancer
- Peutz-Jeghers Syndrome
- Pheochromocytoma/Paraganglioma
- PTEN Hamartoma Tumor Syndrome
- Retinoblastoma
- Rhabdoid Tumor Predisposition Syndrome
- Rhabdomyosarcoma
- Rothmund-Thomson Syndrome
- Tuberous Sclerosis
- Von Hippel-Lindau Disease
Interventions
Not listed
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 5, 2017
- Primary completion
- Mar 30, 2037
- Completion
- Mar 30, 2037
- Last update posted
- Jun 16, 2026
2017 – 2037
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03050268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03050268 live on ClinicalTrials.gov.